BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Novo Nordisk A/S (NVO) Says Victoza Superior to Amylin Pharmaceuticals, Inc. (AMLN) Rival


6/11/2012 7:03:23 AM

The world's largest insulin maker Novo Nordisk A/S (NOVO-B.KO) said late Sunday fresh study results show that its diabetes 2-treating drug Victoza more efficiently lowers blood sugar levels and helps patients lose weight than key competitors' drugs. According to the "real world" study, which is based on the treatment of 1,114 British diabetes patients, the use of Victoza resulted in a greater reduction in average blood sugar levels than U.S. peer Amylin Pharmaceuticals Inc.'s (AMLN) diabetes drug Byetta or dipeptidyl peptidase 4 inhibitors, a group of oral antidiabetes drugs.

Read at Reuters
Read at Fox News
Read at BusinessWeek

   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->